Product
Glenzocimab
1 clinical trial
1 indication
Indication
StrokeClinical trial
A Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Parallel Group, Single Dose, Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic StrokeStatus: Active (not recruiting), Estimated PCD: 2024-01-31